Abstract | OBJECTIVE: To report on 6 weeks of daptomycin treatment for tricuspid valve endocarditis caused by Staphylococcus aureus in a pregnant female in her second trimester. CASE SUMMARY: DISCUSSION:
Infective endocarditis is a common infection encountered in the hospital setting and represents an increased cost burden to institutions due to prolonged lengths of treatment. Antimicrobial resistance, antimicrobial failure, inadequate attainment of effective drug concentrations, drug allergies, and adverse reactions may be factors that limit the use of commonly utilized antimicrobial agents. Therefore, newer therapies like daptomycin may need to be employed in these situations. Although daptomycin is pregnancy category B, limited case reports with neonatal outcomes are reported. CONCLUSIONS: This case provides further support for the safety of daptomycin in pregnancy with the dose of 6 mg/kg, the extended duration of therapy (6 weeks), and the primary exposure in the second trimester.
|
Authors | Jeffrey S Stroup, James Wagner, Terry Badzinski |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 44
Issue 4
Pg. 746-9
(Apr 2010)
ISSN: 1542-6270 [Electronic] United States |
PMID | 20197474
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Daptomycin
|
Topics |
- Anti-Bacterial Agents
(therapeutic use)
- Daptomycin
(therapeutic use)
- Endocarditis, Bacterial
(drug therapy, microbiology)
- Female
- Fever
(etiology)
- Heart Valve Diseases
(drug therapy, microbiology)
- Humans
- Infant, Newborn
- Leukocyte Count
- Microbial Sensitivity Tests
- Pregnancy
- Pregnancy Complications, Infectious
(drug therapy, microbiology)
- Pregnancy Outcome
- Staphylococcal Infections
(drug therapy, microbiology)
- Substance Abuse, Intravenous
(complications)
- Tricuspid Valve
- Young Adult
|